Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors

Clinical trial NCT04802876 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04802876
Sponsor: SOLTI Breast Cancer Research Group
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

MSI-H Colorectal Cancer Melanoma Anal Carcinoma Mesothelioma Triple Negative Breast Cancer Lung Adenocarcinoma Cholangiocarcinoma Cervical Carcinoma Kidney Clear Cell Carcinoma Stomach Adenocarcinoma Esophageal Adenocarcinoma Uterine Adenocarcinoma

Start date: 2021-04-12
Primary completion: 2025-09-30
Enrollment: 184

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.